Literature DB >> 20842460

Retrospective evaluation of the influence of postoperative tumor marker status on survival and patterns of recurrence after surgery for pancreatic cancer based on RECIST guidelines.

Fuyuhiko Motoi1, Toshiki Rikiyama, Yu Katayose, Shin-ichi Egawa, Michiaki Unno.   

Abstract

PURPOSE: The purpose of this study was to obtain a comprehensive understanding of the impact of postoperative tumor marker (TM) normalization on survival after pancreatectomy for pancreatic carcinoma. We propose the concept of surgical RECIST based on residual tumor and TM status.
METHODS: A total of consecutive patients with pancreatic carcinoma underwent pancreatectomy between August 1, 1989, and August 1, 2008. Pre- and postoperative TM values were available for 194 patients. The relationship between TM status, survival, and other clinical and demographic data was determined with univariate log-rank tests and Cox proportional hazards analysis.
RESULTS: Postoperative TM levels remained elevated in 92 patients (47.4%; partial responders). TM levels normalized in 102 patients (52.6%; complete responders). Lymph node metastases, portal vein resection, absence of retroperitoneal clearance, residual tumor, preoperative high CA19-9, and surgical partial response were associated with decreased survival. Nodal stage (P = 0.0227) and surgical RECIST (P = 0.025) were significant predictors of survival. Partial responders had a significantly lower median survival time (P = 0.0008) and significantly higher frequency of hepatic metastasis (P = 0.0299).
CONCLUSIONS: Postresection TM normalization is a strong prognostic factor for pancreatic cancer. The efficacy of pancreatic cancer surgery should be evaluated in the context of both local clearance and serum TM kinetics.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20842460     DOI: 10.1245/s10434-010-1311-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  16 in total

1.  Elevated baseline CA19-9 levels correlate with adverse prognosis in patients with early- or advanced-stage pancreas cancer.

Authors:  Ludmila Katherine Martin; Lai Wei; Elizabeth Trolli; Tanios Bekaii-Saab
Journal:  Med Oncol       Date:  2012-06-24       Impact factor: 3.064

2.  Reappraisal of peritoneal washing cytology in 984 patients with pancreatic ductal adenocarcinoma who underwent margin-negative resection.

Authors:  Sohei Satoi; Yoshiaki Murakami; Fuyuhiko Motoi; Kenichiro Uemura; Manabu Kawai; Masanao Kurata; Masayuki Sho; Ippei Matsumoto; Hiroaki Yanagimoto; Tomohisa Yamamoto; Masamichi Mizuma; Michiaki Unno; Yasushi Hashimoto; Seiko Hirono; Hiroki Yamaue; Goro Honda; Minako Nagai; Yoshiyuki Nakajima; Makoto Shinzeki; Takumi Fukumoto; A-Hon Kwon
Journal:  J Gastrointest Surg       Date:  2014-10-15       Impact factor: 3.452

Review 3.  Current treatment options for pancreatic carcinoma.

Authors:  Emily Castellanos; Jordan Berlin; Dana Backlund Cardin
Journal:  Curr Oncol Rep       Date:  2011-06       Impact factor: 5.075

4.  Is There any Survival Benefit of Maintenance Chemotherapy Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer Patients with Post-Surgery Elevated CA 19-9?

Authors:  Muhammad Wasif Saif; Melissa H Smith; Martin D Goodman; Ronald R Salem
Journal:  JOP       Date:  2020-08-31

5.  18-Fluorodeoxyglucose Positron Emission Tomography Predicts Recurrence in Resected Pancreatic Ductal Adenocarcinoma.

Authors:  Kyohei Ariake; Fuyuhiko Motoi; Hideo Shimomura; Masamichi Mizuma; Shimpei Maeda; Chiaki Terao; Yasuko Tatewaki; Hideo Ohtsuka; Koji Fukase; Kunihiro Masuda; Hiroki Hayashi; Tatsuyuki Takadate; Takeshi Naitoh; Yasuyuki Taki; Michiaki Unno
Journal:  J Gastrointest Surg       Date:  2017-11-08       Impact factor: 3.452

6.  Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy.

Authors:  Sohei Satoi; Hiroaki Yanagimoto; Tomohisa Yamamoto; Chisato Ohe; Chika Miyasaka; Yoshiko Uemura; Satoshi Hirooka; So Yamaki; Hironori Ryota; Taku Michiura; Kentaro Inoue; Yoichi Matsui; Noboru Tanigawa; Masanori Kon
Journal:  Surg Today       Date:  2016-06-04       Impact factor: 2.549

7.  The investigation of the survival time after recurrence in patients with pancreatic ductal adenocarcinoma for individualization of adjuvant chemotherapy.

Authors:  Daisaku Yamada; Hidetoshi Eguchi; Yoshifumi Iwagami; Tadafumi Asaoka; Takehiro Noda; Koichi Kawamoto; Kunihito Gotoh; Shogo Kobayashi; Masaki Mori; Yuichiro Doki
Journal:  Surg Today       Date:  2018-05-17       Impact factor: 2.549

8.  Prognostic Impact of the Initial Postoperative CA19-9 Level in Patients with Extrahepatic Bile Duct Cancer.

Authors:  Yuichiro Kato; Shinichiro Takahashi; Naoto Gotohda; Masaru Konishi
Journal:  J Gastrointest Surg       Date:  2016-06-01       Impact factor: 3.452

9.  Nm23/nucleoside diphosphate kinase-A as a potent prognostic marker in invasive pancreatic ductal carcinoma identified by proteomic analysis of laser micro-dissected formalin-fixed paraffin-embedded tissue.

Authors:  Tatsuyuki Takadate; Tohru Onogawa; Kiyonaga Fujii; Fuyuhiko Motoi; Sayaka Mikami; Tetsuya Fukuda; Makoto Kihara; Takashi Suzuki; Taro Takemura; Takashi Minowa; Nobutaka Hanagata; Kengo Kinoshita; Takanori Morikawa; Keiichi Shirasaki; Toshiki Rikiyama; Yu Katayose; Shinichi Egawa; Toshihide Nishimura; Michiaki Unno
Journal:  Clin Proteomics       Date:  2012-06-27       Impact factor: 3.988

10.  Preoperative serum CA125 levels predict the prognosis in hyperbilirubinemia patients with resectable pancreatic ductal adenocarcinoma.

Authors:  Tao Chen; Min-Gui Zhang; Hua-Xiang Xu; Wen-Quan Wang; Liang Liu; Xian-Jun Yu
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.